Another strong play from medical stock expert Rob Fannon.

Rob says that although Big Pharma stocks are cheap right now - bellwether Pfizer (PFE) is cheaper than it’s ever been - drugmakers are racing off the side of a cliff.

This is because when patents expire drugmakers loose billions of dollars to generic manufacturers.

But biotech drugs can’t be copied easily. And the sector is in an uptrend. Rob recommends using a biotech ETF to play this trend.

Big Pharma is in trouble. Generic competition, patent expirations and slowing sales are all eating into profits.

So how can you turn a profit in this turbulent sector? By investing in contract research organisations, or CROs, says biotech expert Rob Fannon. When the big pharmaceutical companies outsource research to CROs they get paid whether or not the new drugs ever make it to market.

There’s another way to profit too - contract sales organizations, or CSOs. They’re another way for Big Pharma to outsource, but instead of doing research they sell.

You can bet there will be a lot of discussion about interest rates this week, thanks to the release of the producer price index (PPI) report tomorrow (Tuesday) and the U.S. Federal Reserve meeting minutes on Wednesday.

U.S. Federal Reserve policymakers will likely cut its key interest rate to 2.0% from 2.25% this, which would mark the seventh such move since the central bank launched its rate-reduction campaign in mid-September.